1448848-28-9

Upstream product

• 5703-21-9 3,4-dimethoxyphenylacetaldehyde 
• 61871-67-8 3-(3,4-Dimethoxyphenyl)propanal 
• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 
• 1448848-24-5 (R,E)-ethyl5-(3,4-dimethoxyphenyl)-4-hydroxypent-2-enoate 
• 1448848-32-5 C₁₉H₃₀O₄Si 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 1448848-26-7 (R,E)-4-((tert-butyldimethylsilyl)oxy)-5-(3,4-dimethoxyphenyl)pent-2-en-1-ol 
• 1448848-25-6 (R,E)-ethyl-4-((tert-butyldimethylsilyl)oxy)-5-(3,4-dimethoxyphenyl)pent-2-enoate 

Downstream Products

• 1448848-27-8 (R,2E,4E)-6-((tert-Butyldimethylsilyl)oxy)-7-(3,4-dimethoxyphenyl)-N-ethylhepta-2,4-dienamide 
• 1448848-29-0 (R,2E,4E)-6-((tert-butyldimethylsilyl)oxy)-7-(3,4-dimethoxyphenyl)hepta-2,4-dienoic acid 

Relevant academic research and scientific papers

Synthesis and biological evaluation of (-)-kunstleramide and its derivatives

Stereoselective total synthesis of (-)-kunstleramide, a cytotoxic dienamide from the bark of Beilschmiedia kunstleri gamble, has been accomplished by using Keck's asymmetric allylation and Trost isomerization as key reactions. Application of the developed strategy for the synthesis of a series of amide analogues (8-22) was also reported. Furthermore, the synthesized compounds were evaluated for their in vitro anti-proliferative activities against human epithelial lung carcinoma (A549), human epithelial cervical cancer (HeLa), human breast adenocarcinoma (MCF7) and human neuroblastoma (IMR32) cell lines using the SRB assay. All the compounds show moderate anti-proliferative activity against all cell lines. Some of the piperazine derivatives (17-22) strongly inhibit the growth of breast cancer cells with IC50 values of 8-20 μM.

First stereoselective synthesis of cytotoxic (-)-kunstleramide

The first stereoselective synthesis of the cytotoxic (-)-kunstleramide (1) has been reported from simple and commercially available starting material 3,4-dimethoxyphenylpropanol. The key steps involved are the MacMillan α-hydroxylation, Horner-Wadsworth-E